✦ LIBER ✦

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

✍ Scribed by Charles Butts; Andrew Maksymiuk; Glenwood Goss; Denis Soulières; Ernie Marshall; Yvon Cormier; Peter M. Ellis; Allan Price; Ravinder Sawhney; Frank Beier; Martin Falk; Nevin Murray

Book ID: 106124461
Publisher: Springer-Verlag
Year: 2011
Tongue: English
Weight: 225 KB
Volume: 137
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-011-1003-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Multicenter Open-Label Study to Assess

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

✍ Charles Butts; R. Nevin Murray; Colum J. Smith; Peter M. Ellis; Kevin Jasas; And 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 115 KB

PD-070 SIGN: A Phase II, open-label, ran

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

✍ Cufer, T.; Vrdoljak, E. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Prospective, multicenter, randomized, in

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

✍ Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 316 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB